106 related articles for article (PubMed ID: 26161459)
1. Impact of CYP2C8*3 polymorphism on in vitro metabolism of imatinib to N-desmethyl imatinib.
Khan MS; Barratt DT; Somogyi AA
Xenobiotica; 2016; 46(3):278-87. PubMed ID: 26161459
[TBL] [Abstract][Full Text] [Related]
2. Hydroxychloroquine is Metabolized by Cytochrome P450 2D6, 3A4, and 2C8, and Inhibits Cytochrome P450 2D6, while its Metabolites also Inhibit Cytochrome P450 3A
Paludetto MN; Kurkela M; Kahma H; Backman JT; Niemi M; Filppula AM
Drug Metab Dispos; 2023 Mar; 51(3):293-305. PubMed ID: 36446607
[TBL] [Abstract][Full Text] [Related]
3. Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes.
Nebot N; Crettol S; d'Esposito F; Tattam B; Hibbs DE; Murray M
Br J Pharmacol; 2010 Nov; 161(5):1059-69. PubMed ID: 20977456
[TBL] [Abstract][Full Text] [Related]
4. Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response.
Filppula AM; Neuvonen M; Laitila J; Neuvonen PJ; Backman JT
Drug Metab Dispos; 2013 Jan; 41(1):50-9. PubMed ID: 23028140
[TBL] [Abstract][Full Text] [Related]
5. Drug-drug Interaction between Losartan and Paclitaxel in Human Liver Microsomes with Different CYP2C8 Genotypes.
Mukai Y; Senda A; Toda T; Hayakawa T; Eliasson E; Rane A; Inotsume N
Basic Clin Pharmacol Toxicol; 2015 Jun; 116(6):493-8. PubMed ID: 25424246
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of hepatic cirrhosis on the intrinsic clearances of sorafenib and imatinib by CYPs in human liver.
Murray M; Gillani TB; Ghassabian S; Edwards RJ; Rawling T
Eur J Pharm Sci; 2018 Mar; 114():55-63. PubMed ID: 29223619
[TBL] [Abstract][Full Text] [Related]
7. Physiologically-Based Pharmacokinetic Predictions of the Effect of Curcumin on Metabolism of Imatinib and Bosutinib: In Vitro and In Vivo Disconnect.
Adiwidjaja J; Boddy AV; McLachlan AJ
Pharm Res; 2020 Jun; 37(7):128. PubMed ID: 32529309
[TBL] [Abstract][Full Text] [Related]
8. CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia Patients.
Barratt DT; Cox HK; Menelaou A; Yeung DT; White DL; Hughes TP; Somogyi AA
Clin Pharmacokinet; 2017 Aug; 56(8):977-985. PubMed ID: 27995529
[TBL] [Abstract][Full Text] [Related]
9. Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates.
Filppula AM; Laitila J; Neuvonen PJ; Backman JT
Br J Pharmacol; 2012 Apr; 165(8):2787-98. PubMed ID: 22014153
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP-glucuronosyltransferases.
Illingworth NA; Boddy AV; Daly AK; Veal GJ
Br J Pharmacol; 2011 Feb; 162(4):989-99. PubMed ID: 21054342
[TBL] [Abstract][Full Text] [Related]
11. Inter-individual variation in imatinib disposition: any role for prevalent variants of CYP1A2, CYP2C8, CYP2C9, and CYP3A5 in Nigerian CML patients?
Adehin A; Adeagbo BA; Kennedy MA; Bolaji OO; Olugbade TA; Bolarinwa RA; Durosinmi MA
Leuk Lymphoma; 2019 Jan; 60(1):216-221. PubMed ID: 29741432
[TBL] [Abstract][Full Text] [Related]
12. Influence of CYP2C8 polymorphisms on imatinib steady-state trough level in chronic myeloid leukemia and gastrointestinal stromal tumor patients.
Verboom MC; Visser L; Kouwen S; Swen JJ; Diepstraten J; Posthuma WF; Gelderblom H; van Lammeren D; Wilms EB
Pharmacogenet Genomics; 2017 Jun; 27(6):223-226. PubMed ID: 28383355
[TBL] [Abstract][Full Text] [Related]
13. The CYP2B6*6 allele significantly alters the N-demethylation of ketamine enantiomers in vitro.
Li Y; Coller JK; Hutchinson MR; Klein K; Zanger UM; Stanley NJ; Abell AD; Somogyi AA
Drug Metab Dispos; 2013 Jun; 41(6):1264-72. PubMed ID: 23550066
[TBL] [Abstract][Full Text] [Related]
14. Effect of buffer conditions on CYP2C8-mediated paclitaxel 6α-hydroxylation and CYP3A4-mediated triazolam α- and 4-hydroxylation by human liver microsomes.
Kudo T; Ozaki Y; Kusano T; Hotta E; Oya Y; Komatsu S; Goda H; Ito K
Xenobiotica; 2016; 46(3):241-6. PubMed ID: 26290405
[TBL] [Abstract][Full Text] [Related]
15. Oxidative metabolism of 5-methoxy-N,N-diisopropyltryptamine (Foxy) by human liver microsomes and recombinant cytochrome P450 enzymes.
Narimatsu S; Yonemoto R; Saito K; Takaya K; Kumamoto T; Ishikawa T; Asanuma M; Funada M; Kiryu K; Naito S; Yoshida Y; Yamamoto S; Hanioka N
Biochem Pharmacol; 2006 Apr; 71(9):1377-85. PubMed ID: 16510126
[TBL] [Abstract][Full Text] [Related]
16. Demethylation of neferine in human liver microsomes and formation of quinone methide metabolites mediated by CYP3A4 accentuates its cytotoxicity.
Shen Q; Zuo M; Ma L; Tian Y; Wang L; Jiang H; Zhou Q; Zhou H; Yu L; Zeng S
Chem Biol Interact; 2014 Dec; 224():89-99. PubMed ID: 25451576
[TBL] [Abstract][Full Text] [Related]
17. Estimation of the Contribution of CYP2C8 and CYP3A4 in Repaglinide Metabolism by Human Liver Microsomes Under Various Buffer Conditions.
Kudo T; Goda H; Yokosuka Y; Tanaka R; Komatsu S; Ito K
J Pharm Sci; 2017 Sep; 106(9):2847-2852. PubMed ID: 28238899
[TBL] [Abstract][Full Text] [Related]
18. Temsirolimus metabolic pathways revisited.
Shokati T; Hartmann M; Davari B; Klawitter J; Klawitter J; Christians U
Xenobiotica; 2020 Jun; 50(6):640-653. PubMed ID: 31596164
[TBL] [Abstract][Full Text] [Related]
19. Troglitazone thiol adduct formation in human liver microsomes: enzyme kinetics and reaction phenotyping.
Gan J; Qu Q; He B; Shyu WC; Rodrigues AD; He K
Drug Metab Lett; 2008 Aug; 2(3):184-9. PubMed ID: 19356091
[TBL] [Abstract][Full Text] [Related]
20. In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors.
Filppula AM; Neuvonen PJ; Backman JT
Drug Metab Dispos; 2014 Jul; 42(7):1202-9. PubMed ID: 24713129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
